Bone Biologics (BBLG) Interest & Investment Income (2014 - 2026)
Bone Biologics (BBLG) posted quarterly Interest & Investment Income of $47964.0 for Q4 2025, up 136.7% year-over-year from $20264.0 in Q4 2024, and up 1.35% quarter-over-quarter from $47325.0 in Q3 2025.
Powered by 
Analysis
Bone Biologics (BBLG) Interest & Investment Income (2014 - 2026) Analysis & Trends
Bone Biologics (BBLG) has reported Interest & Investment Income for 4 consecutive years, with $47964.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest & Investment Income rose 136.7% year-over-year to $47964.0; the TTM figure through Dec 2025 stood at $121982.0 (up 119.16% YoY), while the FY2025 annual figure was $121984.0, up 119.16% from the prior year.
- Interest & Investment Income grew to $47964.0 in Q4 2025 per BBLG's latest filing, from $47325.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $47964.0 in Q4 2025 and bottomed at $255.0 in Q1 2024.
- Historically, Interest & Investment Income has averaged $16268.5 across 3 years, with a median of $15147.0 in 2024.
- On a YoY basis, Interest & Investment Income climbed as much as 7758.43% in 2025 and fell as far as 56.07% in 2025.
- Bone Biologics' Interest & Investment Income stood at $349.0 in 2023, then surged by 5706.3% to $20264.0 in 2024, then soared by 136.7% to $47964.0 in 2025.
- Business Quant data shows BBLG's Interest & Investment Income at $47964.0 in Q4 2025, $47325.0 in Q3 2025, and $6654.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - | 34,512.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 34,512.00 |
| Dec 31, 2025 | 47,964.00 |
| Sep 30, 2025 | 47,325.00 |
| Jun 30, 2025 | 6,654.00 |
| Mar 31, 2025 | 20,039.00 |
| Dec 31, 2024 | 20,264.00 |
| Sep 30, 2024 | 19,993.00 |
| Jun 30, 2024 | 15,147.00 |
| Mar 31, 2024 | 255.00 |
| Dec 31, 2023 | 349.00 |
| Sep 30, 2023 | 536.00 |
| Jun 30, 2023 | 428.00 |
| Sep 30, 2014 | -877,704.00 |